A Phase I/II, Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Efficacy of HB0043 (Bispecific Antibody Targeting IL-17A and IL-36R) in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS).

The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe HS.

Start Date19 Mar 2025

Sponsor / Collaborator

Shanghai Huaaotai Biopharmaceutical Co., Ltd.

100 Clinical Results associated with HB-0043

100 Translational Medicine associated with HB-0043

100 Patents (Medical) associated with HB-0043

Literatures (Medical) associated with HB-0043

01 May 2025·International Journal of Biological Macromolecules

Developing antibacterial HB43 peptide-loaded chitosan nanoparticles for biofilm treatment

Article

Author: Khodaei, Azin ; Nazmi, Kamran ; Weinans, Harrie ; van Nostrum, Cornelus F ; Amin Yavari, Saber ; van Steenbergen, Mies ; Keikhosravani, Pardis ; van Strijp, Jos ; Bollen, Tim ; Bikker, Floris J

Biofilm-associated infections on medical devices are challenging to treat. Therefore, innovative treatment approaches are needed to penetrate biofilms and eliminate bacteria. With this study, we developed chitosan nanoparticles (CNPs) encapsulating the antibacterial peptide HB43 at increasing CNP/peptide ratios (from 1 to 4 % for P1-CNP, P2-CNP, and P4-CNP, respectively) using the ion gelation method. Our goal was to enhance antibacterial drug delivery inside a methicillin-resistant Staphylococcus aureus (MRSA) biofilm. Our analysis showed a direct correlation between the encapsulation efficacy of HB43 and the physical properties of the CNPs, such as size and zeta potential. P1-CNP was identified as the optimal formulation, characterized by its small size, high encapsulation efficiency, and cationic surface charge. Release studies indicated that HB43 was released in a sustained manner particularly under acidic conditions, which enhanced therapeutic efficacy. We tested the P1-CNP in culture media with pH levels of 7.4 and 5.5 to assess the pH responsiveness of the CNPs and mimic the infection environment. Both conditions showed that the HB43 loaded-CNPs effectively reduced bacterial populations in a dose-dependent manner, with up to a 99.99 % reduction in bacterial load. This study offers a promising new strategy for managing biofilm-associated infections and addressing antibiotic resistance by using CNPs loaded with HB43.

01 Apr 2022·The FEBS JournalQ3 · BIOLOGY

The impact of phosphatidylserine exposure on cancer cell membranes on the activity of the anticancer peptide HB43

Q3 · BIOLOGY

Article

Author: D’Amelio, Nicola ; Herrera‐León, Claudia ; Antonietti, Viviane ; Ramos‐Martín, Francisco ; Sonnet, Pascal

HB43 (FAKLLAKLAKKLL) is a synthetic peptide active against cell lines derived from breast, colon, melanoma, lung, prostate, and cervical cancers. Despite its remarkable spectrum of activity, the mechanism of action at the molecular level has never been investigated, preventing further optimization of its selectivity. The alternation of charged and hydrophobic residues suggests amphipathicity, but the formation of alpha‐helical structure seems discouraged by its short length and the large number of positively charged residues. Using different biophysical and in silico approaches we show that HB43 is completely unstructured in solution but assumes alpha‐helical conformation in the presence of DPC micelles and liposomes exposing phosphatidylserine (PS) used as mimics of cancer cell membranes. Membrane permeabilization assays demonstrate that the interaction leads to the preferential destabilization of PS‐containing vesicles with respect to PC‐containing ones, here used as noncancerous cell mimics. ssNMR reveals that HB43 is able to fluidify the internal structure of cancer‐cell mimicking liposomes while MD simulations show its internalization in such bilayers. This is achieved by the formation of specific interactions between the lysine side chains and the carboxylate group of phosphatidylserine and/or the phosphate oxygen atoms of targeted phospholipids, which could catalyze the formation of the alpha helix required for internalization. With the aim of better understanding the peptide biocompatibility and the additional antibacterial activity, the interaction with noncancerous cell mimicking liposomes exposing phosphatidylcholine (PC) and bacterial mimicking bilayers exposing phosphatidylglycerol (PG) is also described.

15 Mar 2017·The Journal of Infectious DiseasesQ2 · MEDICINE

Eradication of Staphylococcus aureus Biofilm Infections Using Synthetic Antimicrobial Peptides

Q2 · MEDICINE

Article

Author: Forde, Éanna ; Devocelle, Marc ; O'Gara, James P ; Hogan, Siobhan ; Fitzgerald-Hughes, Deirdre ; Zapotoczna, Marta ; O'Neill, Eoghan ; Humphreys, Hilary

Here, we demonstrate that antimicrobial peptides (AMPs) are an effective antibiofilm treatment when applied as catheter lock solutions (CLSs) against S. aureus biofilm infections. The activity of synthetic AMPs (Bac8c, HB43, P18, Omiganan, WMR, Ranalexin, and Polyphemusin) was measured against early and mature biofilms produced by methicillin-resistant S. aureus and methicillin-susceptible S. aureus isolates from patients with device-related infections grown under in vivo-relevant biofilm conditions. The cytotoxic and hemolytic activities of the AMPs against human cells and their immunomodulatory potential in human blood were also characterized. The D-Bac8c2,5Leu variant emerged as the most effective AMP during in vitro studies and was also highly effective in eradicating S. aureus biofilm infection when used in a CLS rat central venous catheter infection model. These data support the potential use of D-Bac8c2,5Leu, alone or in combination with other AMPs, in the treatment of S. aureus intravenous catheter infections.

100 Deals associated with HB-0043

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hidradenitis Suppurativa	Phase 2	China	Shanghai Huaaotai Biopharmaceutical Co., Ltd.	19 Mar 2025
Chronic Kidney Diseases	Preclinical	China	Huabo Biopharm Co Ltd.	01 Jan 2025
Dermatitis, Atopic	Preclinical	China	Huabo Biopharm Co Ltd.	01 Jan 2025
Lupus Nephritis	Preclinical	China	Huabo Biopharm Co Ltd.	01 Jan 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis